| Code | CSB-RA015007MB22HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Zuberitamab, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a cell surface phosphoprotein exclusively expressed on B lymphocytes from the pre-B cell stage through mature B cells, but absent on plasma cells. This transmembrane protein plays a critical role in B cell activation, proliferation, and differentiation through regulation of calcium influx and cell cycle progression. MS4A1 is clinically significant in B cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and various autoimmune disorders where aberrant B cell activity contributes to pathogenesis.
Zuberitamab is a therapeutic monoclonal antibody that binds to MS4A1 and mediates B cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. This biosimilar antibody serves as a valuable research tool for investigating B cell biology, exploring MS4A1-mediated signaling pathways, and developing novel therapeutic strategies for B cell-related disorders. It enables researchers to study mechanisms of B cell depletion and evaluate potential immunotherapeutic approaches.
There are currently no reviews for this product.